IRIS
LAURIA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.034
EU - Europa 3.636
AS - Asia 709
SA - Sud America 15
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 10.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.022
GB - Regno Unito 1.015
IE - Irlanda 811
CN - Cina 621
UA - Ucraina 544
SE - Svezia 388
FR - Francia 262
DE - Germania 210
IT - Italia 177
FI - Finlandia 126
RU - Federazione Russa 45
SG - Singapore 31
CZ - Repubblica Ceca 15
VN - Vietnam 14
BE - Belgio 12
TR - Turchia 12
CA - Canada 10
BR - Brasile 7
NL - Olanda 7
ES - Italia 6
JP - Giappone 6
HR - Croazia 4
AR - Argentina 3
AU - Australia 3
CL - Cile 3
HK - Hong Kong 3
IN - India 3
IR - Iran 3
KG - Kirghizistan 3
MY - Malesia 3
EE - Estonia 2
EU - Europa 2
GR - Grecia 2
ID - Indonesia 2
MX - Messico 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DK - Danimarca 1
EG - Egitto 1
GE - Georgia 1
KR - Corea 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 10.401
Salva come PNG Salva come JPEG
Città #
Fairfield 1.164
Southend 940
Dublin 809
Ashburn 554
Woodbridge 550
Seattle 464
Jacksonville 449
Wilmington 417
Houston 415
Chandler 397
Cambridge 387
Ann Arbor 204
Princeton 173
Nanjing 163
Beijing 136
Siena 90
Nanchang 55
Boardman 52
San Diego 48
San Mateo 39
Helsinki 37
Moscow 37
Shenyang 33
Tianjin 30
Hebei 28
Shanghai 27
Kunming 22
Falls Church 19
London 19
Norwalk 19
Jiaxing 18
Changsha 17
Dearborn 16
San Francisco 16
Singapore 16
Dong Ket 14
Düsseldorf 14
Hangzhou 14
Zhengzhou 14
Brno 13
Menlo Park 13
Brussels 12
Ningbo 12
New York 10
Izmir 9
Lancaster 8
Lanzhou 8
Toronto 8
Washington 8
São Paulo 7
Jinan 6
Málaga 6
Taizhou 6
Changchun 5
Tokyo 5
Chicago 4
Edinburgh 4
Fremont 4
Indiana 4
Los Angeles 4
Rome 4
Zagreb 4
Amsterdam 3
Annecy 3
Bishkek 3
Chiswick 3
Colle Di Val D'elsa 3
Detroit 3
Guangzhou 3
Philadelphia 3
Piacenza 3
Venezia 3
Auburn Hills 2
Berlin 2
Birmingham 2
Bratislava 2
Canberra 2
Central 2
Cherbourg-Octeville 2
Córdoba 2
Fuzhou 2
Groningen 2
Haikou 2
Hounslow 2
Kilburn 2
Lappeenranta 2
Mestre 2
Milan 2
New Bedfont 2
Paliano 2
Prague 2
Shepherdstown 2
Surabaya 2
Tallinn 2
Zanjan 2
Acton 1
Almere Stad 1
Andover 1
Atlanta 1
Bangkok 1
Totale 8.161
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. 210
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 166
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction. 165
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 163
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. 162
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. 162
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 158
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 155
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 154
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 153
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 152
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 152
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. 150
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 149
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 147
Emerging drugs in chronic myelogenous leukaemia 144
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 143
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 142
Towards the pharmacotherapy of hairy cell leukaemia 142
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 142
Predicting the clinical course of Hodgkin lymphoma 142
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 142
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. 141
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 140
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 137
Typical genomic imbalances in primary MALT lymphoma of the orbit 132
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 132
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 132
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 131
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 128
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 127
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. 126
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 123
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 122
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 120
Alternative methods of cladribine administration. 119
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 119
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 118
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 116
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 116
The effects of zoledronic acid on serum lipids in multiple myeloma patients 115
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 112
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 110
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 110
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 109
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 109
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 108
Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey 108
Reply to “Rituximab activity in CD20-positive multiple myeloma” 106
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance 104
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 101
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 100
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 99
Combination therapies to improve the long-term outcome in hairy cell leukemia. 98
Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia treatment 97
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 97
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 96
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia 94
Vaccinoterapia antitumorale: il modello della leucemia mieloide cronica. 94
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 94
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 92
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib 92
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients 91
Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes 90
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency 89
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma 87
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 86
CD30 positive (non-anaplastic) peripheral T cell lymphoma of the thyroid gland 86
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate 85
Favorable impact of low dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non Hodgkin’s lymphomas 83
Evaluation of Ph+/CD34+ residual cells in chronic myeloid leukemia patients after long lasting treatment with imatinib mesylate 81
Bcr-abl peptides for chronic myeloid leukemia. 80
Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years 80
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 80
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 80
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 80
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 80
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia : a new treatment schedule effective and safer in preventing infective complications 79
EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES (MABTHERA) IN PATIENTS WITH PROGRESSED HAIRY CELL LEUKEMIA. 74
Deletion 9q in a patient with concomitant myelodisplasia and non-Hodgkin lymphoma 73
CMLVAX100 Peptide Vaccinations induce Peptide Specific "cytotoxic" CD4+ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response 73
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 73
Hyperlipidemic myeloma 71
Case-control study of multidrug resistance phenotype and response to induction treatment includine or not fludarabine in newly diagnosed acute myeloid leukemia patients 71
Imatinib mesylate in the treatment of c-kit positive acute myeloid leukemia: is the real target? 69
CD4+/CD45RA+ “naive” T cells and immunological response to influenza virus vaccine in B-cell chromnic lymphocitic leukemia patients 68
Imatinib plus CMLVAX100 (P210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia (CML) showing persistent residual disease during treatment with imatinib mesylate 68
Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia 66
Low-dose fludarabine and cyclophosohamide in elderly patients with B-cell chronic lymphocytic leukemia refractory in conventional theraphy 66
Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment. 64
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 61
Long-lasting complete remission in patients with hairy cell leukemia trated with 2-CdA: a 5-year survey 56
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC) 55
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia 51
Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Entercoccus faecium 46
null 34
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study 23
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines 21
297. Gozzetti A.,Tozzuoli D., Crupi R., Gentili S., Raspadori D., Fabbri A., Lauria F. A t(20;21) (q2;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. 4
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 4
Totale 10.447
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.948
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.948
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.954 359 106 210 503 208 218 258 372 243 240 67 170
2020/20211.677 91 209 56 171 91 211 59 263 200 91 137 98
2021/20221.070 68 146 49 82 43 38 47 40 59 135 108 255
2022/20231.515 112 127 239 208 149 311 25 105 140 19 57 23
2023/20241.030 44 17 84 65 22 294 391 4 5 12 5 87
2024/202516 16 0 0 0 0 0 0 0 0 0 0 0
Totale 10.453